Skip to search boxSkip to navigationSkip to main content

Cardiotoxicity with immune system targeting drugs: A meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials

  • Mohamed Rahouma(corresponding author)
    ,
  • Nagla Abdel Karim
    ,
  • Massimo Baudo
    ,
  • Maha Yahia
    ,
  • Mohamed Kamel
    ,
  • Ihab Eldessouki
*Corresponding author for this work
  • Cairo University
    ,
  • University of Cincinnati
    ,
  • Cornell University
    ,
  • University of Texas MD Anderson Cancer Center
    ,
  • University of Turin
Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Background: With antiprogrammed death receptor-1 (anti-PD-L1) therapy, a recent meta-analysis reported higher incidence of cutaneous, endocrine and gastrointestinal complications especially with dual anti-PD-L1 immunotherapy (IMM). Methods: Our primary outcome was assessment of all cardiotoxicity grades in IMM compared with different treatments, thus a systemic review and a meta-analysis on randomized clinical trials (RCTs) were done. Results: We included 11 RCTs with 6574 patients (3234 patients in IMM arm vs 3340 patients in the other arm). Three non-small-cell lung cancer RCTs, seven melanoma RCTs and only one prostatic cancer RCT met the inclusion criteria. There were five RCTs that compared monoimmunotherapy to chemotherapy "(n = 2631 patients)". No difference exists in all cardiotoxicity grades or high-grade cardiotoxicity (p > 0.05). Lung cancer exhibited a higher response rate and lower mortality in IMM. Conclusion: There was no reported statistically significant cardiotoxicity associated with anti-PD/PD-L1 use. Lung cancer subgroups showed better response and survival rates.

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 725-735 (11 pages)

Journal (Volume, Issue Number)

Immunotherapy (Volume 11, Issue 8)

Publication milestones

  • Published - 05/15/2019

Publication status

Published - 05/15/2019

ISSN

1750-743X

Publication IDs

  • Scopus: 85065989264
  • PubMed: 31088241

Publication metrics

Metrics

SciVal
FWCI
0.55
SciVal
Author count
20
SciVal
citations
8
SciVal
Paper percentile
85
Fractional count
1
Fractional count
0.05
Fractional count
19
Fractional count
0.95
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
34
Captures
67